Vivonics is excited to announce that we have been awarded a $319,000 grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) for Phase I development of our Galvanic Vestibular Stimulation (GVS) technology to treat the symptoms of Ménière's disease, led jointly by our CEO Gordon Hirschman and Devin McCaslin, Ph.D. of the University of Michigan, with key support from Mindy Bishop, Ph.D. at Vivonics. Ménière's disease is a debilitating illness characterized by episodic attacks of vertigo, which can make many activities of daily living dangerous or impossible. GVS is an innovative technology that allows for treatment of vertigo and balance issues by applying electricity via the skin to the vestibular system, a key component of balance in humans. Vivonics has been developing GVS technology over the past decade for many different applications to explore new ways of treating these conditions without pharmaceuticals or invasive implants, and this project is the latest extension of that work. An important part of this program will include a human study in collaboration with Dr. McCaslin to demonstrate the effectiveness of the system. With this technology, sufferers of Ménière's disease will have a new way of treating their symptoms without the side effects of drugs or other conventional methods, allowing them to resume their normal lives in safety and comfort.

Thanks to everyone at Vivonics for making this happen!